Bristol-Myers Squibb (BMY) Revenue — Quarter Ended Mar 31, 2024
Revenue increased compared to both the prior quarter and the same quarter last year. The growth was supported by higher net product sales and alliance revenues.
Key takeaway
Quarter ended Mar 31, 2024 · FY2024 Q1
Revenue increased compared to both the prior quarter and the same quarter last year. The growth was supported by higher net product sales and alliance revenues.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$11.9B
Revenue reported for this quarter.
Quarter-over-quarter
+3.4%
Change from the immediately preceding quarter.
Year-over-year
+4.7%
Change from the comparable year-ago quarter.
Trailing four quarters
$45.5B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Jun 30, 2023 | $11.2B | -5.6% |
| Sep 30, 2023 | $11B | -2.2% |
| Dec 31, 2023 | $11.5B | +0.6% |
| Mar 31, 2024 | $11.9B | +4.7% |
Revenue performance
Total revenues rose, driven by an increase in net product sales and alliance and other revenues.
Quarterly comparison
Compared to the immediately preceding quarter, revenue improved. Compared to the same quarter one year earlier, revenue also showed an increase.
What to watch
The significant increase in acquired in-process research and development expenses should be monitored for its impact on future profitability.